Literature DB >> 3529780

Long-term results of stereotactic radiosurgery to the pituitary gland in Cushing's disease.

M Degerblad, T Rähn, G Bergstrand, M Thorén.   

Abstract

Gamma radiation from 60Co delivered with stereotactic technique was given to the pituitary gland in 35 patients, aged 18-65 years, with Cushing's disease. The doses were 70-100 Gy in each single irradiation. The size of the sella turcica was normal in the majority of the patients. The observation time was 3-9 years in 29 patients. Out of them, 14 (48%) obtained clinical remission and normal urinary cortisol after one irradiation. Eight achieved remission after two to four irradiations. In total, 22 out of 29 patients (76%) obtained remission. In 12 of them remission was obtained in 1 year and in another 10 within 3 years. No recurrences were observed. Improvement was seen in 2 patients after one and three irradiations. Bilateral adrenalectomy was performed in 5 patients owing to unsatisfactory effect of irradiation. Pituitary insufficiency with gonadotropin, thyrotropin or corticotropin failure was demonstrated in 12 of 22 patients in remission. This occurred 4 months to 7 years after the first irradiation. Another 6 patients were followed less than 3 years after the first irradiation. Two obtained remission after the first treatment, whereas the other 4 improved. Stereotactic pituitary irradiation is suggested as a non-invasive therapeutic alternative in Cushing's disease for example in patients with considerable surgical risk or as a supplement to pituitary microsurgery.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3529780     DOI: 10.1530/acta.0.1120310

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  14 in total

Review 1.  Neurology of the pituitary gland.

Authors:  J R Anderson; N Antoun; N Burnet; K Chatterjee; O Edwards; J D Pickard; N Sarkies
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-06       Impact factor: 10.154

Review 2.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

3.  Failure of long-term therapy with sodium valproate in Cushing's disease.

Authors:  A Colao; R Pivonello; F S Tripodi; F Orio; D Ferone; G Cerbone; C Di Somma; B Merola; G Lombardi
Journal:  J Endocrinol Invest       Date:  1997 Jul-Aug       Impact factor: 4.256

4.  Failure in management of pituitary tumors discussion of 3 cases.

Authors:  B Sutter; M Steiner; M B Lopes; D Prasad; L Steiner
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

5.  Setup margins and geometric uncertainties in intensity-modulated radiation therapy in treating pituitary adenomas: the experience of Lyon Sud Hospital.

Authors:  B De Bari; I Shakir Shakir; T Chekrine; L Lestrade; V Favrel
Journal:  Radiol Med       Date:  2012-10-22       Impact factor: 3.469

Review 6.  Applications of radiotherapy and radiosurgery in the management of pediatric Cushing's disease: a review of the literature and our experience.

Authors:  Jay Jagannathan; Adam S Kanter; Claire Olson; Jonathan H Sherman; Edward R Laws; Jason P Sheehan
Journal:  J Neurooncol       Date:  2008-06-21       Impact factor: 4.130

Review 7.  Conventional fractionated radiation therapy vs. radiosurgery for selected benign intracranial lesions (arteriovenous malformations, pituitary adenomas, and acoustic neuromas).

Authors:  L B Marks
Journal:  J Neurooncol       Date:  1993-09       Impact factor: 4.130

Review 8.  Modern techniques for pituitary radiotherapy.

Authors:  G Minniti; D C Gilbert; M Brada
Journal:  Rev Endocr Metab Disord       Date:  2009-06       Impact factor: 6.514

Review 9.  Cushing's disease: radiation therapy.

Authors:  Mary Lee Vance
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

Review 10.  An approach to the management of patients with residual Cushing's disease.

Authors:  Lewis S Blevins; Nader Sanai; Sandeep Kunwar; Jessica K Devin
Journal:  J Neurooncol       Date:  2009-04-19       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.